Search company, investor...

InflammX Therapeutics

Founded Year

2020

Stage

Series A | Alive

Total Raised

$15.39M

Last Raised

$8.36M | 2 yrs ago

About InflammX Therapeutics

InflammX Therapeutics is a healthcare company based in Florida.

Headquarters Location

275 Bayshore Blvd., Unit 1607

Tampa, Florida, 33606,

United States

Loading...

Loading...

Latest InflammX Therapeutics News

Dry Age-Related Macular Degeneration Pipeline Insights Report 2024 | Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals

Feb 19, 2024

DelveInsight’s, “Dry Age-related Macular Degeneration Pipeline Insight 2024”  report provides comprehensive insights about 70+ companies and 80+ pipeline drugs in Dry Age-related Macular Degeneration (Dry-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Key Takeaways from the Dry Age-Related Macular Degeneration Pipeline Report DelveInsight’s Dry Age-Related Macular Degeneration pipeline report depicts a robust space with 70+ active players working to develop 80+ pipeline therapies for Dry Age-Related Macular Degeneration treatment. The leading companies working in the Dry Age-Related Macular Degeneration market include Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others. Promising Dry Age-Related Macular Degeneration Pipeline Therapies in the various stages of development include RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others. On January 2023, Luxa Biotechnology Inc. announced a study of Phase 1 & 2 Clinical Trials for RPESC-RPE-4W. The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD. On August 2023, Smilebiotek Zhuhai Limited announced a study of Phase 2 Clinical Trials for QA102. This is a phase 2, double-masked, randomized, placebo-controlled, dose-response study. The primary objective of the study is to evaluate the efficacy of QA102 oral capsules on the development of GA or CNV in high-risk eyes. Request a sample and discover the recent advances in Dry Age-Related Macular Degeneration Treatment Drugs @  Dry Age-Related Macular Degeneration Pipeline Outlook Report The Dry Age-Related Macular Degeneration pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Dry Age-Related Macular Degeneration drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Dry Age-Related Macular Degeneration clinical trial landscape. Dry Age-Related Macular Degeneration Overview Age-related macular degeneration (AMD) is a degenerative disease of the center area of the ocular-posterior segment (the macula lutea) that causes slow degeneration in central vision and severe disability in affected persons. Tinlarebant (LBS-008): Belite Bio Dry Age-Related Macular Degeneration Pipeline Therapeutics Assessment There are approx. 70+ key companies which are developing the therapies for Dry Age-related Macular Degeneration. The Dry Age-Related Macular Degeneration companies which have their Dry Age-related Macular Degeneration drug candidates in the most advanced stage, i.e. Phase III include, Alkeus Pharmaceuticals. Coverage- Global Dry Age-Related Macular Degeneration Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Dry Age-Related Macular Degeneration Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Dry Age-Related Macular Degeneration Companies- Molecular Partners, Stealth BioTherapeutics, Regenerative Patch Technologies, Aevitas Therapeutics, NGM Biopharmaceuticals, InflammX Therapeutics, Lineage Cell Therapeutics, Alexion AstraZeneca Rare Disease, Belite Bio, Katairo, Cognition Therapeutics, Apellis Pharmaceuticals, Galimedix Therapeutics, Amarna Therapeutics, 4D Molecular Therapeutics, Aviceda Therapeutics, Isarna Therapeutics, and others. Dry Age-Related Macular Degeneration Pipeline Therapies- RPESC-RPE-4W, PRIMA, QA102, Active Comparator CT1812, ASP7317, Tacrolimus, OCU410, GT005, AVD-104, and others. Dry Age-related Macular Degeneration Key Products Dry Age-related Macular Degeneration- Unmet Needs Dry Age-related Macular Degeneration- Market Drivers and Barriers Dry Age-related Macular Degeneration- Future Perspectives and Conclusion Dry Age-related Macular Degeneration Analyst Views Dry Age-related Macular Degeneration Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact

InflammX Therapeutics Frequently Asked Questions (FAQ)

  • When was InflammX Therapeutics founded?

    InflammX Therapeutics was founded in 2020.

  • Where is InflammX Therapeutics's headquarters?

    InflammX Therapeutics's headquarters is located at 275 Bayshore Blvd., Unit 1607, Tampa.

  • What is InflammX Therapeutics's latest funding round?

    InflammX Therapeutics's latest funding round is Series A.

  • How much did InflammX Therapeutics raise?

    InflammX Therapeutics raised a total of $15.39M.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.